Fiche publication
Date publication
novembre 2025
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ANTONI Delphine
Tous les auteurs :
Antoni D, Mesny E, El Kabbaj O, Robert C, Quintin K, Feuvret L, Biau J, Jacob J
Lien Pubmed
Résumé
Gliomas are the most frequent malignant primary brain tumours in adults. The proximity of organs at risk, the infiltrating nature, and the radioresistance of gliomas have to be taken into account in the choice of prescribed dose and technique of radiotherapy. The management of glioma patients is based on clinical factors (age, Karnofsky performance status) and tumour characteristics (histology, molecular biology, tumour location), and strongly depends on available and associated treatments, such as surgery, radiotherapy, and chemotherapy. The knowledge of molecular biomarkers is currently essential; they are increasingly evolving as additional factors that facilitate diagnostics and therapeutic decision-making. We present the update of the recommendations of the Société française de radiothérapie oncologique (the French Society for Radiation Oncology) on the indications and the technical procedures for performing radiotherapy in patients with gliomas.
Mots clés
Anaplastic glioma, Biologie moléculaire, Biomarkers, Diffuse glioma, Glioblastoma, Glioblastome, Gliome anaplasique, Gliome diffus, Radiotherapy, Radiothérapie, Recommandations, Recommendations, SFRO, Société française de radiothérapie oncologique
Référence
Cancer Radiother. 2025 11 21;29(7-8):104774
